Long-Term Follow-up of the Italian Flexible Sigmoidoscopy Screening Trial.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
01 2022
Historique:
pubmed: 9 11 2021
medline: 15 2 2022
entrez: 8 11 2021
Statut: ppublish

Résumé

Recent reports showed that the protective effect of flexible sigmoidoscopy (FS) screening was maintained up to17 years, although differences were reported by sex. To assess long-term reduction of colorectal cancer (CRC) incidence and mortality after a single FS screening. Parallel randomized controlled trial. (ISRCTN registry number: 27814061). 6 centers in Italy. Persons aged 55 to 64 years expressing interest in having FS screening if invited, recruited from 1995 to 1999 and followed until 2012 (incidence) and 2014 to 2016 (mortality). Eligible persons were randomly assigned (1:1 ratio) to either the once-only FS screening group or control (usual care) group. Incidence and mortality rate ratios (RRs) and rate differences. A total of 34 272 persons (17 136 in each group) were included in the analysis; 9911 participants had screening in the intervention group. Median follow-up was 15.4 years for incidence and 18.8 years for mortality. Incidence of CRC was reduced by 19% (RR, 0.81 [95% CI, 0.71 to 0.93]) in the intention-to-treat (ITT) analysis, comparing the intervention with the control group, and by 33% (RR, 0.67 [CI, 0.56 to 0.81]) in the per protocol (PP) analysis, comparing participants screened in the intervention group with the control persons. Colorectal cancer mortality was reduced by 22% (RR, 0.78 [CI, 0.61 to 0.98]) in the ITT analysis and by 39% (RR, 0.61 [CI, 0.44 to 0.84]) in the PP analysis. Incidence of CRC was statistically significantly reduced among both men and women. Colorectal cancer mortality was statistically significantly reduced among men (ITT RR, 0.73 [CI, 0.54 to 0.97]) but not among women (ITT RR, 0.90 [CI, 0.59 to 1.37]). Self-selection of volunteers from the general population sample targeted for recruitment may limit generalizability. The strong protective effect of a single FS screening for CRC incidence and mortality was maintained up to 15 and 19 years, respectively. Italian Association for Cancer Research, Italian National Research Council, Istituto Oncologico Romagnolo, Fondo "E. Tempia," University of Milan, and Local Health Unit ASL-Torino.

Sections du résumé

BACKGROUND
Recent reports showed that the protective effect of flexible sigmoidoscopy (FS) screening was maintained up to17 years, although differences were reported by sex.
OBJECTIVE
To assess long-term reduction of colorectal cancer (CRC) incidence and mortality after a single FS screening.
DESIGN
Parallel randomized controlled trial. (ISRCTN registry number: 27814061).
SETTING
6 centers in Italy.
PARTICIPANTS
Persons aged 55 to 64 years expressing interest in having FS screening if invited, recruited from 1995 to 1999 and followed until 2012 (incidence) and 2014 to 2016 (mortality).
INTERVENTION
Eligible persons were randomly assigned (1:1 ratio) to either the once-only FS screening group or control (usual care) group.
MEASUREMENTS
Incidence and mortality rate ratios (RRs) and rate differences.
RESULTS
A total of 34 272 persons (17 136 in each group) were included in the analysis; 9911 participants had screening in the intervention group. Median follow-up was 15.4 years for incidence and 18.8 years for mortality. Incidence of CRC was reduced by 19% (RR, 0.81 [95% CI, 0.71 to 0.93]) in the intention-to-treat (ITT) analysis, comparing the intervention with the control group, and by 33% (RR, 0.67 [CI, 0.56 to 0.81]) in the per protocol (PP) analysis, comparing participants screened in the intervention group with the control persons. Colorectal cancer mortality was reduced by 22% (RR, 0.78 [CI, 0.61 to 0.98]) in the ITT analysis and by 39% (RR, 0.61 [CI, 0.44 to 0.84]) in the PP analysis. Incidence of CRC was statistically significantly reduced among both men and women. Colorectal cancer mortality was statistically significantly reduced among men (ITT RR, 0.73 [CI, 0.54 to 0.97]) but not among women (ITT RR, 0.90 [CI, 0.59 to 1.37]).
LIMITATION
Self-selection of volunteers from the general population sample targeted for recruitment may limit generalizability.
CONCLUSION
The strong protective effect of a single FS screening for CRC incidence and mortality was maintained up to 15 and 19 years, respectively.
PRIMARY FUNDING SOURCE
Italian Association for Cancer Research, Italian National Research Council, Istituto Oncologico Romagnolo, Fondo "E. Tempia," University of Milan, and Local Health Unit ASL-Torino.

Identifiants

pubmed: 34748376
doi: 10.7326/M21-0977
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

36-45

Investigateurs

A Carnevali (A)
A Agnolucci (A)
P Ceccatelli (P)
F Mirri (F)
A Penna (A)
G Genta (G)
A Marutti (A)
A Guelfi (A)
B Gatteschi (B)
G Fiori (G)
G Fabbretti (G)
S Gasperoni (S)
A Bertone (A)
M Pennazio (M)
M Spandre (M)
Marco Silvani (M)
M Demaria (M)

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Carlo Senore (C)

University Hospital Città della Salute e della Scienza, Turin, Italy (C.S., E.R., P.A., N.S.).

Emilia Riggi (E)

University Hospital Città della Salute e della Scienza, Turin, Italy (C.S., E.R., P.A., N.S.).

Paola Armaroli (P)

University Hospital Città della Salute e della Scienza, Turin, Italy (C.S., E.R., P.A., N.S.).

Luigina Bonelli (L)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy (L.B., S.S., C.C.).

Stefania Sciallero (S)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy (L.B., S.S., C.C.).

Marco Zappa (M)

ISPRO, Florence, Italy (M.Z., C.B.V.).

Arrigo Arrigoni (A)

FPO-IRCCS Candiolo Cancer Institute,Turin, Italy (A.A.).

Claudia Casella (C)

IRCCS Ospedale Policlinico San Martino, Genoa, Italy (L.B., S.S., C.C.).

Cristiano Crosta (C)

IRCCS European Institute of Oncology, Milan, Italy (C.C.).

Fabio Falcini (F)

Romagna Cancer Registry, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Forlì, Italy (F.F., O.G.).

Franco Ferrero (F)

Infermi Hospital, Biella, Italy (F.F.).

Mario Fracchia (M)

Mauriziano Umberto I Hospital, Turin, Italy (M.F.).

Orietta Giuliani (O)

Romagna Cancer Registry, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Forlì, Italy (F.F., O.G.).

Mauro Risio (M)

FPO-IRCCS Candiolo Cancer Institute, Turin, Italy (M.R.).

Antonio G Russo (AG)

Agency for Health Protection of the Metropolitan Area of Milan, Milan, Italy (A.G.R.).

Carmen Beatriz Visioli (CB)

ISPRO, Florence, Italy (M.Z., C.B.V.).

Stefano Rosso (S)

Piedmont Cancer Registry, University Hospital Città della Salute e della Scienza, Turin, Italy (S.R.).

Nereo Segnan (N)

University Hospital Città della Salute e della Scienza, Turin, Italy (C.S., E.R., P.A., N.S.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH